Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia.

Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Ahmed I, Aljurf M, Askar M, Auletta JJ, Bhatt V, Bredeson C, Chhabra S, Gadalla S, Gajewski J, Gale RP, Gergis U, Hematti P, Hildebrandt GC, Inamoto Y, Kitko C, Khandelwal P, MacMillan ML, Majhail N, Marks DI, Mehta P, Nishihori T, Olsson RF, Pawarode A, Diaz MA, Prestidge T, Qayed M, Rangarajan H, Ringden O, Saad A, Savani BN, Seo S, Shah A, Shah N, Schultz KR, Solh M, Spitzer T, Szer J, Teshima T, Verdonck LF, Williams KM, Wirk B, Wagner J, Yared JA, Weisdorf DJ.

Blood Adv. 2019 May 14;3(9):1441-1449. doi: 10.1182/bloodadvances.2018030171.

2.

Benefits and challenges with diagnosing chronic and late acute GvHD in children using the NIH consensus criteria.

Cuvelier GDE, Nemecek ER, Wahlstrom JT, Kitko CL, Lewis VA, Schechter T, Jacobsohn DA, Harris AC, Pulsipher MA, Bittencourt H, Choi SW, Caywood EH, Kasow KA, Bhatia M, Oshrine BR, Flower A, Chaudhury S, Coulter D, Chewning JH, Joyce M, Savaşan S, Pawlowska AB, Megason GC, Mitchell D, Cheerva AC, Lawitschka A, West LJ, Pan B, Al-Hamarneh YN, Halevy A, Schultz KR.

Blood. 2019 May 1. pii: blood.2019000216. doi: 10.1182/blood.2019000216. [Epub ahead of print]

PMID:
31043425
3.

An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.

Hartwell MJ, Özbek U, Holler E, Renteria AS, Major-Monfried H, Reddy P, Aziz M, Hogan WJ, Ayuk F, Efebera YA, Hexner EO, Bunworasate U, Qayed M, Ordemann R, Wölfl M, Mielke S, Pawarode A, Chen YB, Devine S, Harris AC, Jagasia M, Kitko CL, Litzow MR, Kröger N, Locatelli F, Morales G, Nakamura R, Reshef R, Rösler W, Weber D, Wudhikarn K, Yanik GA, Levine JE, Ferrara JL.

JCI Insight. 2018 Aug 23;3(16). pii: 124015. doi: 10.1172/jci.insight.124015. eCollection 2018 Aug 23. No abstract available.

4.

A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801.

Carpenter PA, Logan BR, Lee SJ, Weisdorf DJ, Johnston L, Costa LJ, Kitko CL, Bolaños-Meade J, Sarantopoulos S, Alousi AM, Abhyankar S, Waller EK, Mendizabal A, Zhu J, O'Brien KA, Lazaryan A, Wu J, Nemecek ER, Pavletic SZ, Cutler CS, Horowitz MM, Arora M; BMT CTN.

Haematologica. 2018 Nov;103(11):1915-1924. doi: 10.3324/haematol.2018.195123. Epub 2018 Jun 28.

5.

Chemokines: a novel chronic GVHD target.

Kitko C, Levine JE.

Blood. 2018 Apr 12;131(15):1636-1638. doi: 10.1182/blood-2018-02-829101. No abstract available.

6.

MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD.

Major-Monfried H, Renteria AS, Pawarode A, Reddy P, Ayuk F, Holler E, Efebera YA, Hogan WJ, Wölfl M, Qayed M, Hexner EO, Wudhikarn K, Ordemann R, Young R, Shah J, Hartwell MJ, Chaudhry MS, Aziz M, Etra A, Yanik GA, Kröger N, Weber D, Chen YB, Nakamura R, Rösler W, Kitko CL, Harris AC, Pulsipher M, Reshef R, Kowalyk S, Morales G, Torres I, Özbek U, Ferrara JLM, Levine JE.

Blood. 2018 Jun 21;131(25):2846-2855. doi: 10.1182/blood-2018-01-822957. Epub 2018 Mar 15.

PMID:
29545329
7.

Outcomes following autologous hematopoietic stem cell transplant for patients with relapsed Wilms' tumor: a CIBMTR retrospective analysis.

Malogolowkin MH, Hemmer MT, Le-Rademacher J, Hale GA, Mehta PA, Smith AR, Kitko C, Abraham A, Abdel-Azim H, Dandoy C, Angel Diaz M, Gale RP, Guilcher G, Hayashi R, Jodele S, Kasow KA, MacMillian ML, Thakar M, Wirk BM, Woolfrey A, Thiel EL.

Bone Marrow Transplant. 2017 Nov;52(11):1549-1555. doi: 10.1038/bmt.2017.178. Epub 2017 Sep 4.

8.

Prospective computerized monitoring of cognitive functioning before and after blood and marrow transplantation.

Votruba KL, Hoodin F, Giordani B, Kentor R, Couriel DR, Kitko CL.

Bone Marrow Transplant. 2017 Aug;52(8):1215-1217. doi: 10.1038/bmt.2017.105. Epub 2017 Jun 12. No abstract available.

PMID:
28604666
9.

B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality.

Saliba RM, Sarantopoulos S, Kitko CL, Pawarode A, Goldstein SC, Magenau J, Alousi AM, Churay T, Justman H, Paczesny S, Reddy P, Couriel DR.

Bone Marrow Transplant. 2017 Jul;52(7):1010-1015. doi: 10.1038/bmt.2017.73. Epub 2017 May 8.

10.

Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and Marrow Transplant Research Report.

Khandelwal P, Millard HR, Thiel E, Abdel-Azim H, Abraham AA, Auletta JJ, Boulad F, Brown VI, Camitta BM, Chan KW, Chaudhury S, Cowan MJ, Angel-Diaz M, Gadalla SM, Gale RP, Hale G, Kasow KA, Keating AK, Kitko CL, MacMillan ML, Olsson RF, Page KM, Seber A, Smith AR, Warwick AB, Wirk B, Mehta PA.

Biol Blood Marrow Transplant. 2017 Aug;23(8):1342-1349. doi: 10.1016/j.bbmt.2017.04.018. Epub 2017 Apr 24.

11.

An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.

Hartwell MJ, Özbek U, Holler E, Renteria AS, Major-Monfried H, Reddy P, Aziz M, Hogan WJ, Ayuk F, Efebera YA, Hexner EO, Bunworasate U, Qayed M, Ordemann R, Wölfl M, Mielke S, Pawarode A, Chen YB, Devine S, Harris AC, Jagasia M, Kitko CL, Litzow MR, Kröger N, Locatelli F, Morales G, Nakamura R, Reshef R, Rösler W, Weber D, Wudhikarn K, Yanik GA, Levine JE, Ferrara JL.

JCI Insight. 2017 Feb 9;2(3):e89798. doi: 10.1172/jci.insight.89798. Erratum in: JCI Insight. 2018 Aug 23;3(16):.

12.

Infectious Risk after Allogeneic Hematopoietic Cell Transplantation Complicated by Acute Graft-versus-Host Disease.

Miller HK, Braun TM, Stillwell T, Harris AC, Choi S, Connelly J, Couriel D, Goldstein S, Kitko CL, Magenau J, Pawarode A, Reddy P, Riwes M, Yanik GA, Levine JE.

Biol Blood Marrow Transplant. 2017 Mar;23(3):522-528. doi: 10.1016/j.bbmt.2016.12.630. Epub 2016 Dec 22.

13.

Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial.

Kitko CL, Braun T, Couriel DR, Choi SW, Connelly J, Hoffmann S, Goldstein S, Magenau J, Pawarode A, Reddy P, Schuler C, Yanik GA, Ferrara JL, Levine JE.

Biol Blood Marrow Transplant. 2016 May;22(5):862-8. doi: 10.1016/j.bbmt.2015.11.002. Epub 2015 Nov 6.

14.

Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research.

Burke MJ, Verneris MR, Le Rademacher J, He W, Abdel-Azim H, Abraham AA, Auletta JJ, Ayas M, Brown VI, Cairo MS, Chan KW, Diaz Perez MA, Dvorak CC, Egeler RM, Eldjerou L, Frangoul H, Guilcher GMT, Hayashi RJ, Ibrahim A, Kasow KA, Leung WH, Olsson RF, Pulsipher MA, Shah N, Shah NN, Thiel E, Talano JA, Kitko CL.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2154-2159. doi: 10.1016/j.bbmt.2015.08.023. Epub 2015 Aug 29.

15.

Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth.

Mody RJ, Wu YM, Lonigro RJ, Cao X, Roychowdhury S, Vats P, Frank KM, Prensner JR, Asangani I, Palanisamy N, Dillman JR, Rabah RM, Kunju LP, Everett J, Raymond VM, Ning Y, Su F, Wang R, Stoffel EM, Innis JW, Roberts JS, Robertson PL, Yanik G, Chamdin A, Connelly JA, Choi S, Harris AC, Kitko C, Rao RJ, Levine JE, Castle VP, Hutchinson RJ, Talpaz M, Robinson DR, Chinnaiyan AM.

JAMA. 2015 Sep 1;314(9):913-25. doi: 10.1001/jama.2015.10080.

16.

Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series.

Pawarode A, Mineishi S, Reddy P, Braun TM, Khaled YA, Choi SW, Magenau JM, Harris AC, Connelly JA, Kitko CL, Parkin BL, Goldstein SC, Yanik GA, Levine JE, Ferrara JL, Couriel DR.

Biol Blood Marrow Transplant. 2016 Jan;22(1):54-60. doi: 10.1016/j.bbmt.2015.07.021. Epub 2015 Jul 26.

17.

FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML.

Song Y, Magenau J, Li Y, Braun T, Chang L, Bixby D, Hanauer DA, Chughtai KA, Gatza E, Couriel D, Goldstein S, Pawarode A, Reddy P, Riwes M, Connelly J, Harris A, Kitko C, Levine J, Yanik G, Parkin B, Choi SW.

Bone Marrow Transplant. 2016 Apr;51(4):511-520. doi: 10.1038/bmt.2015.170. Epub 2015 Jul 20.

18.

Transplantation Outcomes for Children with Hypodiploid Acute Lymphoblastic Leukemia.

Mehta PA, Zhang MJ, Eapen M, He W, Seber A, Gibson B, Camitta BM, Kitko CL, Dvorak CC, Nemecek ER, Frangoul HA, Abdel-Azim H, Kasow KA, Lehmann L, Gonzalez Vicent M, Diaz Pérez MA, Ayas M, Qayed M, Carpenter PA, Jodele S, Lund TC, Leung WH, Davies SM.

Biol Blood Marrow Transplant. 2015 Jul;21(7):1273-7. doi: 10.1016/j.bbmt.2015.04.008. Epub 2015 Apr 10.

19.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report.

Carpenter PA, Kitko CL, Elad S, Flowers ME, Gea-Banacloche JC, Halter JP, Hoodin F, Johnston L, Lawitschka A, McDonald GB, Opipari AW, Savani BN, Schultz KR, Smith SR, Syrjala KL, Treister N, Vogelsang GB, Williams KM, Pavletic SZ, Martin PJ, Lee SJ, Couriel DR.

Biol Blood Marrow Transplant. 2015 Jul;21(7):1167-87. doi: 10.1016/j.bbmt.2015.03.024. Epub 2015 Mar 31.

20.

Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report.

Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, Pidala J, Olivieri A, Martin PJ, Przepiorka D, Pusic I, Dignan F, Mitchell SA, Lawitschka A, Jacobsohn D, Hall AM, Flowers ME, Schultz KR, Vogelsang G, Pavletic S.

Biol Blood Marrow Transplant. 2015 Jun;21(6):984-99. doi: 10.1016/j.bbmt.2015.02.025. Epub 2015 Mar 19.

21.

Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission.

Magenau JM, Braun T, Reddy P, Parkin B, Pawarode A, Mineishi S, Choi S, Levine J, Li Y, Yanik G, Kitko C, Churay T, Frame D, Riwes MM, Harris A, Bixby D, Couriel DR, Goldstein SC.

Ann Hematol. 2015 Jun;94(6):1033-41. doi: 10.1007/s00277-015-2349-4. Epub 2015 Mar 19.

PMID:
25784222
22.

Extracorporeal photopheresis in prevention and treatment of acute GVHD.

Kitko CL, Levine JE.

Transfus Apher Sci. 2015 Apr;52(2):151-6. doi: 10.1016/j.transci.2015.02.001. Epub 2015 Feb 16. Review.

PMID:
25748231
23.

Predictive value of bronchiolitis obliterans syndrome stage 0p in chronic graft-versus-host disease of the lung.

Abedin S, Yanik GA, Braun T, Pawarode A, Magenau J, Goldstein SC, Levine JE, Kitko CL, Couriel DR.

Biol Blood Marrow Transplant. 2015 Jun;21(6):1127-31. doi: 10.1016/j.bbmt.2015.02.006. Epub 2015 Feb 14.

24.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.

Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J, Weisdorf D, Treister NS, Cheng GS, Kerr H, Stratton P, Duarte RF, McDonald GB, Inamoto Y, Vigorito A, Arai S, Datiles MB, Jacobsohn D, Heller T, Kitko CL, Mitchell SA, Martin PJ, Shulman H, Wu RS, Cutler CS, Vogelsang GB, Lee SJ, Pavletic SZ, Flowers ME.

Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1. doi: 10.1016/j.bbmt.2014.12.001. Epub 2014 Dec 18.

25.

National Institutes of Health State of the Science Symposium in Therapeutic Apheresis: scientific opportunities in extracorporeal photopheresis.

Ratcliffe N, Dunbar NM, Adamski J, Couriel D, Edelson R, Kitko CL, Levine JE, Morgan S, Schneiderman J, Sloan S, Wu Y, Szczepiorkowski ZM, Cooling L; American Society for Apheresis.

Transfus Med Rev. 2015 Jan;29(1):62-70. doi: 10.1016/j.tmrv.2014.09.004. Epub 2014 Oct 15. Review.

PMID:
25459074
26.

Parametric response mapping as an indicator of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.

Galbán CJ, Boes JL, Bule M, Kitko CL, Couriel DR, Johnson TD, Lama V, Telenga ED, van den Berge M, Rehemtulla A, Kazerooni EA, Ponkowski MJ, Ross BD, Yanik GA.

Biol Blood Marrow Transplant. 2014 Oct;20(10):1592-8. doi: 10.1016/j.bbmt.2014.06.014. Epub 2014 Jun 18.

27.

Exercise and stress management training prior to hematopoietic cell transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902.

Jacobsen PB, Le-Rademacher J, Jim H, Syrjala K, Wingard JR, Logan B, Wu J, Majhail NS, Wood W, Rizzo JD, Geller NL, Kitko C, Faber E, Abidi MH, Slater S, Horowitz MM, Lee SJ.

Biol Blood Marrow Transplant. 2014 Oct;20(10):1530-6. doi: 10.1016/j.bbmt.2014.05.027. Epub 2014 Jun 6.

28.

Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.

Gatza E, Braun T, Levine JE, Ferrara JL, Zhao S, Wang T, Chang L, Harris A, Pawarode A, Kitko C, Magenau JM, Yanik GA, Couriel DR, Goldstein S, Connelly J, Reddy P, Paczesny S, Choi SW.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1426-34. doi: 10.1016/j.bbmt.2014.05.023. Epub 2014 Jun 2.

29.

Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens.

Bitan M, He W, Zhang MJ, Abdel-Azim H, Ayas MF, Bielorai B, Carpenter PA, Cairo MS, Diaz MA, Horan JT, Jodele S, Kitko CL, Schultz KR, Kletzel M, Kasow KA, Lehmann LE, Mehta PA, Shah N, Pulsipher MA, Prestidge T, Seber A, Shenoy S, Woolfrey AE, Yu LC, Davies SM.

Blood. 2014 Mar 6;123(10):1615-20. doi: 10.1182/blood-2013-10-535716. Epub 2014 Jan 16.

30.

Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome.

Hitzler JK, He W, Doyle J, Cairo M, Camitta BM, Chan KW, Diaz Perez MA, Fraser C, Gross TG, Horan JT, Kennedy-Nasser AA, Kitko C, Kurtzberg J, Lehmann L, O'Brien T, Pulsipher MA, Smith FO, Zhang MJ, Eapen M, Carpenter PA; CIBMTR Pediatric Cancer Working Committee.

Pediatr Blood Cancer. 2014 Jun;61(6):1126-8. doi: 10.1002/pbc.24918. Epub 2014 Jan 4.

31.

Plasma CXCL9 elevations correlate with chronic GVHD diagnosis.

Kitko CL, Levine JE, Storer BE, Chai X, Fox DA, Braun TM, Couriel DR, Martin PJ, Flowers ME, Hansen JA, Chang L, Conlon M, Fiema BJ, Morgan R, Pongtornpipat P, Lamiman K, Ferrara JL, Lee SJ, Paczesny S.

Blood. 2014 Jan 30;123(5):786-93. doi: 10.1182/blood-2013-08-520072. Epub 2013 Dec 20.

32.

Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial.

Choi SW, Braun T, Chang L, Ferrara JL, Pawarode A, Magenau JM, Hou G, Beumer JH, Levine JE, Goldstein S, Couriel DR, Stockerl-Goldstein K, Krijanovski OI, Kitko C, Yanik GA, Lehmann MH, Tawara I, Sun Y, Paczesny S, Mapara MY, Dinarello CA, DiPersio JF, Reddy P.

Lancet Oncol. 2014 Jan;15(1):87-95. doi: 10.1016/S1470-2045(13)70512-6. Epub 2013 Nov 30.

33.

Impact of psychological screening on routine outpatient care of hematopoietic cell transplantation survivors.

Hoodin F, Zhao L, Carey J, Levine JE, Kitko C.

Biol Blood Marrow Transplant. 2013 Oct;19(10):1493-7. doi: 10.1016/j.bbmt.2013.07.019. Epub 2013 Jul 25.

34.

Outcome of transplantation for acute myelogenous leukemia in children with Down syndrome.

Hitzler JK, He W, Doyle J, Cairo M, Camitta BM, Chan KW, Diaz Perez MA, Fraser C, Gross TG, Horan JT, Kennedy-Nasser AA, Kitko C, Kurtzberg J, Lehmann L, O'Brien T, Pulsipher MA, Smith FO, Zhang MJ, Eapen M, Carpenter PA; CIBMTR Pediatric Cancer Working Committee.

Biol Blood Marrow Transplant. 2013 Jun;19(6):893-7. doi: 10.1016/j.bbmt.2013.02.017. Epub 2013 Mar 1.

35.

Management of noninfectious lung injury following hematopoietic cell transplantation.

Yanik G, Kitko C.

Curr Opin Oncol. 2013 Mar;25(2):187-94. doi: 10.1097/CCO.0b013e32835dc8a5. Review.

PMID:
23340330
36.

Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes.

Harris AC, Kitko CL, Couriel DR, Braun TM, Choi SW, Magenau J, Mineishi S, Pawarode A, Yanik G, Levine JE.

Haematologica. 2013 Feb;98(2):179-84. doi: 10.3324/haematol.2012.073189. Epub 2012 Oct 12.

37.

Impact of immune modulation with in vivo T-cell depletion and myleoablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemia.

Veys P, Wynn RF, Ahn KW, Samarasinghe S, He W, Bonney D, Craddock J, Cornish J, Davies SM, Dvorak CC, Duerst RE, Gross TG, Kapoor N, Kitko C, Krance RA, Leung W, Lewis VA, Steward C, Wagner JE, Carpenter PA, Eapen M.

Blood. 2012 Jun 21;119(25):6155-61. doi: 10.1182/blood-2012-01-405795. Epub 2012 May 9.

38.

TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes.

Choi SW, Stiff P, Cooke K, Ferrara JL, Braun T, Kitko C, Reddy P, Yanik G, Mineishi S, Paczesny S, Hanauer D, Pawarode A, Peres E, Rodriguez T, Smith S, Levine JE.

Biol Blood Marrow Transplant. 2012 Oct;18(10):1525-32. doi: 10.1016/j.bbmt.2012.03.013. Epub 2012 Mar 30.

39.

Fibrotic and sclerotic manifestations of chronic graft-versus-host disease.

Kitko CL, White ES, Baird K.

Biol Blood Marrow Transplant. 2012 Jan;18(1 Suppl):S46-52. doi: 10.1016/j.bbmt.2011.10.021. Review. No abstract available.

40.

Soluble tumor necrosis factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation.

Yanik GA, Mineishi S, Levine JE, Kitko CL, White ES, Vander Lugt MT, Harris AC, Braun T, Cooke KR.

Biol Blood Marrow Transplant. 2012 Jul;18(7):1044-54. doi: 10.1016/j.bbmt.2011.11.031. Epub 2011 Dec 10.

41.

Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies.

Magenau J, Tobai H, Pawarode A, Braun T, Peres E, Reddy P, Kitko C, Choi S, Yanik G, Frame D, Harris A, Erba H, Kujawski L, Elenitoba-Johnson K, Sanks J, Jones D, Paczesny S, Ferrara J, Levine J, Mineishi S.

Blood. 2011 Oct 13;118(15):4258-64. doi: 10.1182/blood-2011-06-358010. Epub 2011 Aug 12.

42.

Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease.

Martin PJ, Storer BE, Carpenter PA, Couriel DR, Flowers ME, Gupta V, Hsu JW, Jagasia M, Kitko CL, Maziarz RT, Rowley SD, Shaughnessy PJ, van Besien K, Weisdorf D, Lee SJ.

Biol Blood Marrow Transplant. 2011 Jan;17(1):124-32. doi: 10.1016/j.bbmt.2010.06.018. Epub 2010 Jun 30.

43.

Elafin is a biomarker of graft-versus-host disease of the skin.

Paczesny S, Braun TM, Levine JE, Hogan J, Crawford J, Coffing B, Olsen S, Choi SW, Wang H, Faca V, Pitteri S, Zhang Q, Chin A, Kitko C, Mineishi S, Yanik G, Peres E, Hanauer D, Wang Y, Reddy P, Hanash S, Ferrara JL.

Sci Transl Med. 2010 Jan 6;2(13):13ra2. doi: 10.1126/scitranslmed.3000406.

44.

Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease.

Magenau JM, Qin X, Tawara I, Rogers CE, Kitko C, Schlough M, Bickley D, Braun TM, Jang PS, Lowler KP, Jones DM, Choi SW, Reddy P, Mineishi S, Levine JE, Ferrara JL, Paczesny S.

Biol Blood Marrow Transplant. 2010 Jul;16(7):907-14. doi: 10.1016/j.bbmt.2010.02.026. Epub 2010 Mar 17.

45.

Successful unrelated donor cord blood transplantation for Glanzmann's thrombasthenia.

Kitko CL, Levine JE, Matthews DC, Carpenter PA.

Pediatr Transplant. 2011 May;15(3):e42-6. doi: 10.1111/j.1399-3046.2009.01251.x.

PMID:
19849809
46.

Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease.

Martin PJ, Storer BE, Rowley SD, Flowers ME, Lee SJ, Carpenter PA, Wingard JR, Shaughnessy PJ, DeVetten MP, Jagasia M, Fay JW, van Besien K, Gupta V, Kitko C, Johnston LJ, Maziarz RT, Arora M, Jacobson PA, Weisdorf D.

Blood. 2009 May 21;113(21):5074-82. doi: 10.1182/blood-2009-02-202937. Epub 2009 Mar 6.

47.

A biomarker panel for acute graft-versus-host disease.

Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R, Misek DE, Cooke KR, Kitko CL, Weyand A, Bickley D, Jones D, Whitfield J, Reddy P, Levine JE, Hanash SM, Ferrara JL.

Blood. 2009 Jan 8;113(2):273-8. doi: 10.1182/blood-2008-07-167098. Epub 2008 Oct 2.

48.

Plasma elevations of tumor necrosis factor-receptor-1 at day 7 postallogeneic transplant correlate with graft-versus-host disease severity and overall survival in pediatric patients.

Kitko CL, Paczesny S, Yanik G, Braun T, Jones D, Whitfield J, Choi SW, Hutchinson RJ, Ferrara JL, Levine JE.

Biol Blood Marrow Transplant. 2008 Jul;14(7):759-65. doi: 10.1016/j.bbmt.2008.04.002.

49.

Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival.

Choi SW, Kitko CL, Braun T, Paczesny S, Yanik G, Mineishi S, Krijanovski O, Jones D, Whitfield J, Cooke K, Hutchinson RJ, Ferrara JL, Levine JE.

Blood. 2008 Aug 15;112(4):1539-42. doi: 10.1182/blood-2008-02-138867. Epub 2008 May 23.

50.

Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease.

Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW, Hutchinson RJ, Jones D, Khaled Y, Kitko CL, Bickley D, Krijanovski O, Reddy P, Yanik G, Ferrara JL.

Blood. 2008 Feb 15;111(4):2470-5. Epub 2007 Nov 27.

Supplemental Content

Support Center